ArticleApplied microbiology and biotechnology2026
Mucin O-glycan degradation by GH101 underpins mucosal persistence of Bifidobacterium bifidum PRL2010.
Article in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Host-derived mucin O-glycans constitute a key chemical component of the human intestinal niche and are continuously encountered by gut-adapted bifidobacterial cells, thereby playing a pivotal role in host-microbe interactions. Among these microbes, Bifidobacterium bifidum is one of the most persistent members of the human gut microbiota. Comparative genomic analyses of mucosa-associated strains of this species have revealed a gene conserved across its pangenome, predicted to encode a GH101 glycoside hydrolase involved in mucin degradation. In this study, we performed a molecular characterization of the GH101 enzyme encoded by B. bifidum PRL2010. Insertional mutagenesis of the GH101 gene from the PRL2010 genome resulted in a marked reduction in bacterial adhesion to mucin-secreting epithelial cells, along with a significant growth difference when N-acetyl-galactosamine was provided as the sole carbon source. These findings indicate that GH101 mediates the initial cleavage of O-GalNAc core 1 structures, representing a crucial step for the adhesion to human mucosa. However, this enzyme represents only one component of the broader set of glycosidases required for the complete degradation of host mucins. Overall, our results establish a mechanistic link between metabolic specialization and ecological fitness, providing insights into how mucin-adapted commensals may contribute to interactions with the human gut mucosa. KEY POINTS: • The GH101 glycoside hydrolase of Bifidobacterium bifidum PRL2010 plays a pivotal role in host mucin utilization by initiating the cleavage of O-GalNAc core 1 structures. • Insertional mutant of the GH101 gene impairs both mucosal adhesion and growth on N-acetyl-galactosamine. • These findings reveal a mechanistic connection between mucin glycan metabolism and ecological fitness by mucin-adapted bifidobacterial commensals.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.